1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Oesophageal cancer

Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

Awaiting development [GID-TA11440] Expected publication date: TBC

  • Project information
  • Project documents

NIHRIO BN: 33898-Durvalumab-FLOT-for-Gastro-Oesophageal-Junction-Cancer-V1.0-SEP2023-NON-CONF.pdf (nihr.ac.uk)